ABSTRACT

Background: Head and neck mucosal melanoma account for 2 to 8% of head and neck melanomas, the majority of which arises in the nasal cavity or paranasal sinuses. The aim of this report was to review our experience on sinonasal malignant melanomas (SNMM) treated over a long period of time at a tertiary referral hospital.

Methods: Clinical records of all of the patients operated on for SNMM at the Social Security Hospital and private clinics in Quito, Ecuador, were reviewed. Nineteen patients had histologically proven diagnosis. Eleven patients were men and mean age was 64. The most common presenting symptoms were nasal obstruction and epistaxis. Most tumors were located at the nasal fossa. Extranasal extension was present in 11 patients. Twelve had stage III-IV tumors. All patients were treated by surgery. Postoperative radiotherapy was given to 7.

Results: Local recurrence (11 events) occurred in 9 cases. These 11 events were treated with surgery in 8, eventually associated to radiation therapy (RT) and chemotherapy (CT). Eight out of these 9 patients died. Five overall survival was 46%. Death was related to local disease and distant metastases. All stage I tumor patients are alive.

Conclusions: Most sinusonal melanomas have a poor prognosis, mainly attributed to initial advanced local disease, local recurrence and distant metastasis. Surgery is the mainstay treatment, followed by radiotherapy, according to the T category.

Keywords: Mucosal, Melanoma, Sinonasal

INTRODUCTION

Melanomas are tumors arising from melanocytes, which are neuroectodermal-derived cells located in the basal layers of the skin, skin adnexa, and some mucosal membranes. Common sites for skin melanomas are the lower extremities. Less common sites of involvement are oral and genital mucosa, conjunctiva, orbit, esophagus, nasal mucosa or nasopharynx, vagina, and the leptomeninges.

Primary skin melanoma of the head and neck accounts for 25-30% of all melanomas. Head and neck mucosal melanoma (HNMM) is a rare and aggressive disease that makes up less than 1% of all melanoma cases in the United States and 2% to 8% of head and neck melanomas. In a study carried out by Marcus, 452 cases of HNMM of the Surveillance, Epidemiology, and End Results (SEER) 9 registry of the United States between 1987 and 2009, were identified. According to this study, the incidence of HNMM in the United States has been rising since 1987. This trend has been driven primarily by increased incidence of nasal cavity melanomas. Most melanomas are located in the nasal cavity or paranasal sinuses.

The aim of this report was to review our experience on sinonasal malignant melanomas (SNMM) treated over a long period of time at a tertiary referral hospital.
METHODS

The clinical records of all of the patients operated on for SNMM at the Social Security Hospital and private clinics in Quito, Ecuador, South America, from 1981 to 2013, were reviewed. Nineteen patients had histologically confirmed diagnosis of primary mucosal melanoma. Demographic and clinical features as well as and treatment modalities were reviewed. Actuarial survival analysis was calculated according to the Kaplan-Meier method.

Fifteen patients were mestizo, 3 whites and one Amerindian. The sex ratio was 1.4:1 (11 men, 8 women). Mean age of presentation was 64 (range: 49 to 81). The most common presenting symptoms nasal obstruction in 12 and epistaxis in 8; other symptoms were pain in 2 and nasal secretion, swelling of the cheek, ocular proptosis and epiphora in one case, each. Mean duration of symptoms was 6 months (range: 1 to 24). Tumors were located at the nasal fossa in 13 cases, the maxillary sinus in 1 and the ethmoid sinus in one; both nasal as maxillary sinus involvement occurred in 4 patients. Extransal extension appeared at the cheek skin in 4 patients, the cheek subcutaneous tissue in 1, the orbit in 2, the cribiform plate in 2 and the ptério-maxillary fossa and gum in one, each. TNM distribution according to the AJCC classification system which seems to be the best staging system for patients with mucosal melanomas of the sinonasal tract appears on Table 1. No patient had distant metastases initially.

Seven patients had stage I or II tumors whereas 12 had stage III or IV tumors. All patients were treated by surgery, performed by the senior author; initially, in our service, in 15 cases and for recurrent tumors in the other four. In the latter cases, initial surgery, mostly wide tumor resection, had been done by other oncological or ENT surgeons. Surgical modalities appear on Table II. Wide tumor resection was performed in 9 patients. An adaptation of maxillectomy was performed in 8 cases (one of them associated to orbital exenteration) and a crano-facial resection in 2 (Figure 1-3). A N1 case underwent a supraomohyoid dissection and a N2a case, a radical modified neck dissection (RMND). Postoperative radiotherapy (4800 cGy to 5800 cGy) was given to 7 patients (2 stage II, 3 stage III and 2 stage IVA).

RESULTS

Mean follow-up was 35 (range: 2-214) months. Three patients were lost to follow up. Local recurrence occurred in 9 cases; one recurrence in 7 and 2 recurrences in 2 patients. These 11 events were treated with surgery in 8 cases (3 patients refused treatment), associated to radiation therapy (RT) in 2 patients and chemotherapy (CT) in another. Eight out of these 9 patients with local recurrence died (2 for local disease, 5 for additional metastases and one with not related disease) and only one is currently alive. Neck recurrence occurred in 2 patients in association to local recurrence; they were treated with a RMND in one case and a parotidectomy and RMND in the other. Distant metastases during follow up occurred in 9 patients and they were located in the liver in 5, the brain in 4, the lungs in 2, the bone in 2, the bone marrow in 2 and the spleen in 1. All of them died. Five-year overall survival was 46%. Twelve patients died during follow up. Death was related to tumor progression in 2 patients, distant metastases in 7, both local disease and distant metastases in 2 and not related disease in one (Table 3). No patient with stage I tumor died with disease.

| Stage | Local disease | Metastases | Local and metastatic disease | Not related disease | Total |
|-------|---------------|------------|-----------------------------|---------------------|-------|
| I     | -             | -          | 1                           | -                   | 1/3   |
| II    | 1             | 2          | -                           | -                   | 3/4   |
| III   | -             | 3          | -                           | -                   | 3/5   |
| IVA   | 2             | 1          | 2                           | -                   | 4/7*  |

*2 lost to follow up

Table 1: TNM and stage distribution.

| N0 | N1 | N2a | N2b | Total | Stage |
|----|----|-----|-----|-------|-------|
| T1 | 3  | 0   | 0   | 3     | I     |
| T2 | 4  | 0   | 0   | 4     | II    |
| T3 | 4  | 1   | 0   | 5     | III   |
| T4A| 5  | 0   | 1   | 7     | IVA   |
| Total | 16 | 1   | 1   | 19    | Total 19 |

Table 2: Initial surgical procedures performed in our institution.

| Type of surgery          | Number of cases |
|--------------------------|-----------------|
| Wide local excision      | 9               |
| Lateronasal approach     | 3               |
| Denker                   | 3               |
| Degloving, vestibular or endoscopic | 3 |
| Extension adapted maxillectomy | 7 |
| Total maxillectomy + orbit exenteration | 1 |
| Craneo-facial resection  | 2               |

Table 3: Cause of death according to stage.
DISCUSSION

Among the cancers that arise in nasal cavity and paranasal sinuses, mucosal melanomas are rare in comparison to squamous cell carcinomas. Case reports have been commonly published and most series have included a limited number of cases (Table 4).

Peak incidence has been reported to be between the fifth and eighth decade.\(^{11,12}\) Mean age in our patients was 64. In the study of Marcus with patients of SEER 9 registry (4), 237 (52.4%) patients were female, and 215 (47.6%) were male. In other smaller series and in ours, a slightly more common presentation in males than in females was found.\(^{11-15}\)

The presentation depends on the size and site of the lesion. At initial presentation, these tumors can be fairly advanced, due to the ample space available to accommodate their growth in the nasal cavities and sinuses. Twelve of our 19 patients presented with advanced lesions, T3 and T4a, and duration of symptoms was certainly long before the first consultation. The majority of the patients present with epistaxis and progressively increasing nasal obstruction.\(^{13}\) However, other less common symptoms such as pain, nasal secretion, swelling of the cheek, ocular proptosis and epiphora can be present as in our series.

Surgery has been the mainstay of the treatment of these tumors, provided they are resectable.\(^{16}\) The modality of the surgical procedure must be adapted to the extension of the disease. The tumor must be excised completely even if a one block resection may be not always usually feasible.

The incidence of regional lymph node metastasis on admission is approximately 5-15%.\(^{11}\) Eleven per cent in the current series. The submandibular lymph nodes are the most commonly involved. A comprehensive neck dissection must be performed in case of regional disease.

Historically, mucosal melanoma was characterized as a radioresistant disease, but recent observations suggest that radiotherapy has a significant role in their treatment. Adjuvant RT is usually well-tolerated and should be used for patients with either large bulky primary disease or regional metastases. It reduces the likelihood of local-regional failure but probably does not enhance survival.\(^{15-19}\) However, some authors have reported improved survival is selected groups with postoperative RT.\(^{20-22}\)

Patients with unresectable local disease or that cannot be operated for medical reasons or those who do not agree for surgery should be considered for radiotherapy alone as a definitive management, whereas chemotherapy should be reserved for patients with systemic disease. Long-term survival for patients treated with RT alone remains uncertain.\(^{22,23}\) Christopherson of the University of Florida in Gainesville in recent report of 21 cases of
MMHN concluded that the prognosis for patients treated with definitive RT is less promising than for those who receive surgery and postoperative RT. \textsuperscript{18} Bonner demonstrated the usefulness of concomitant chemoradiotherapy in squamous cell carcinomas of the head and neck region, and indicated a possible role of primary concomitant chemoradiation in mucosal melanomas as well. \textsuperscript{24}

### Table 4: Recent series on nasal and paranasal region melanomas.

| Institution | Years       | Number of cases |
|-------------|-------------|-----------------|
| University of Campinas, Piracicaba, São Paulo, Brazil | 1979-1997 | 46 |
| Institut Gustave Roussy, Villejuif, France | 1990-2004 | 50 |
| Finish Nationwide Study, Finland | 1993-2004 | 58 |
| The University of Texas M. D. Anderson Cancer Center, Houston, USA | 1980-2005 | 34 |
| Shantou Central Hospital of Sun-Yat-Sen University, Shantou, China | 1994-2005 | 15 |
| Chang Gung Memorial Hospital, Tao-Yuan, Taiwan | 1971-2006 | 40 |
| Fachklinik Hornheide, Westfälische Wilhelms University of Münster, Münster, Germany | 1991-2006 | 23 |
| University of Miami, Miami, USA | 1990-2007 | 11 |
| Memorial Sloan-Kettering Cancer Center, New York, USA | 1992-2007 | 24 |
| Huriez Hospital, University of Lille, France. | 1991-2008 | 25 |
| Yokohama City University School of Medicine, Kanagawa, Japan | 1992-2010 | 13 |
| La Timone Universitary Hospital Center, Aix-Marseille, France | 1995-2010 | 35 |
| Present series | 1981-2013 | 19 |

Several new biologic and immunomodulatory treatments are currently being investigated for use in patients with mucosal melanoma. KIT and BRAF mutations, which are accessible for present targeted therapies, are only rarely present in SNMMs, whereas NRAS mutations seem to be relatively more frequent. \textsuperscript{25} Newer radiotherapy modalities like intensity-modulated radiotherapy (IMRT) and three-dimensional conformal radiotherapy (3-D-CRT) are being investigated and show some promise for use in treating these tumors in the future.

The natural course is marked by early local recurrences, metastasis to lymph nodes and distant metastases. The likelihood of local recurrence after resection for HNMM is approximately 50%. \textsuperscript{19} In a series of 69 HNMM patients treated at the Gustave Roussy Institut (IGR), thirty-seven patients (54%) experienced local disease recurrence and 47 patients (68%) developed distant metastasis at the IGR. \textsuperscript{20}

The 5-year survival rates for HNMM vary from approximately 20 to 50%, although the median time to relapse is roughly 1 year or less (19). Overall survival for HNMM has ranged between 49.5% and 64.7% at 2 years and between 20% and 51.5% at 5 years in the most recent series. \textsuperscript{13,16,20,21,26-30} HNMM, and particularly SNMM, are primarily impacted by advanced T stage and the presence of regional metastases. \textsuperscript{15,19,21,28} Additionally, the presence of distant metastasis at the time of diagnosis is also a bad prognostic factor. The patients treated at the IGR with advanced T classification and pN > 0 stage had a earlier distant metastasis, disease-free and overall survival compared with patients with early T-classification and pN < 0 stage. \textsuperscript{20}

Tumor extension to the sphenoid sinus had a significant negative impact on survival in the Finnish Nationwide Study. \textsuperscript{27} Initial surgery with en bloc resection, has been reported as a prognostic factor for outcomes for local control and survival. \textsuperscript{24,25} Histological features such as pigmentation and pseudopapillary architecture are associated with worse outcome. \textsuperscript{15} It seems that other factors such as age and sex do not affect the prognosis. \textsuperscript{11,12,30}

In conclusion, a high index of suspicion is required to make an early diagnosis, particularly by ENT surgeons who may have problems in diagnosing this disease owing to its rarity. However, advanced disease can be easily diagnosed clinically.

As a rule, patients with localized disease should undergo surgery followed by postoperative radiotherapy for better local control of the disease, according to the T category. Poor prognosis may be attributed mainly to initial advanced local disease, local recurrence and distant metastasis.

**Funding:** No funding sources  
**Conflict of interest:** None declared  
**Ethical approval:** The study was approved by the institutional ethics committee
REFERENCES

1. Goldsmith HS. Melanoma: an overview. Cancer J Clin. 1979;29:194-215.
2. Lee PS, Shimizu KT, Tran LM, Juillard G, Calcaterra TC. Mucosal melanoma of the head and neck: The impact of local control on survival. Laryngoscope. 1994;104:121-6.
3. Mclaughlin CC, Wu XC, Jemal A, Martin HJ, Roche LM, Chen VW. Incidence of noncutaneous melanomas in the U.S. Cancer. 2003;103:1007-7.
4. Marcus DM, Marcus RP, Prabhu RS, Owenikoko TK, Lawson DH, Switchenko J, et al. Rising incidence of mucosal melanoma of the head and neck in the United States. J Skin Cancer. 2012;2012:231693.
5. Mckinnon JG, Kokal WA, Neifeld JP, Kay S. Natural history and treatment of mucosal melanoma. J Surg Oncol. 1989;4:222-5.
6. Stern SJ, Guillamondegui OM. Mucosal melanoma of the head and neck. Head Neck. 1991;13:22-7.
7. Kanetaka S, Tsukuda M, Takahashi M, Komatsu M, Niho T, Horiuuchi C, Matsuda H. Mucosal melanoma of the head and neck. Exp Ther Med. 2011;2:907-10.
8. Dwivedi R, Dwivedi R, Kazi R, Kumar S, Agarwal SP. Mucosal melanoma of nasal cavity and paranasal sinus. J Can Res Ther. 2008;4:200-2.
9. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Handbook. Springer-Verlag. 2010:93-101.
10. Michel J, Court A, Fakhry N, Braustein D, Monestier S, Richard MA, et al. Sinonasal mucosal melanomas: the prognostic value of tumor classifications. Head Neck. 2014;36:311-6.
11. Batsakis JG, Suarez P, Naggar AK. Mucosal melanomas of the head and neck. Ann Otol Rhinol Laryngol. 1998;107:626-30.
12. Snow GB, Waal I. Mucosal melanomas of the head and neck. Otolaryng Clin North Am. 1988;19:549-64.
13. Huang SF, Liao CT, Kan CR, Chen IH. Primary mucosal melanoma of the nasal cavity and paranasal sinuses: 12 years of experience. J Otolaryngol. 2007;36:124-9.
14. Benevenuto D, Andrade BA, Piña AR, León JE, Almeida O, Altemani A. Primary nasal mucosal melanoma in Brazil: clinicopathologic and immunohistochemical study of 12 patients. Ann Diagn Pathol. 2012;16:344-9.
15. Moreno MA, Roberts DB, Kupferman ME, DeMonte F, El-Naggar AK, Williams M, Rosenthal DS, Hanna EY. Mucosal melanoma of the nose and paranasal sinuses, a contemporary experience from the M. D. Anderson Cancer Center. Cancer. 2010;116:2215-23.
16. Gal TJ, Silver N, Huang B. Demographics and treatment trends in sinonasal mucosal melanoma. Laryngoscope. 2011;121:2026-33.
17. Wu AJ, Gomez J, Zheng JE, Chan K, Gomez DR, Wolden SL, et al. Radiotherapy after surgical resection for head and neck mucosal melanoma. Am J Clin Oncol. 2010;33:281-5.
18. Christopherson K, Malyapa RS, Werning JW, Morris CG, Kirwan J, Mendenhall WM. Radiation therapy for mucosal melanoma of the head and neck. Am J Clin Oncol. 2015;38:87-9.
19. Mendenhall WM, Amdur RJ, Hinerman RW, Werning JW, Villaret DB, Mendenhall NP. Head and neck mucosal melanoma. Am J Clin Oncol. 2005;28:626-30.
20. Temam S, Mamelle G, Marandas P, Wibault P, Avril MF, Janot F, Julieron M, Schwab G, Luboinski B. Postoperative radiotherapy for primary mucosal melanoma of the head and neck. Cancer. 2005;103:313-9.
21. Saigal K, Weed DT, Reis IM, Markoe AM, Wolfson AH, Nguyen-Spery J. Mucosal melanomas of the head and neck: the role of postoperative radiation therapy. ISRN Oncol. 2012;2012:785131.
22. Gilligan D, Slevin NJ. Radical radiotherapy for 28 cases of mucosal melanoma in nasal cavity and sinuses. Br J Radiol. 1991;64:1147-50.
23. Harwood AR, Cummings BJ. Radiotherapy for mucosal melanomas. Int J Radiat Oncol Biol Phys. 1982;8:1121-6.
24. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous cell carcinoma of head and neck. N Engl J Med. 2006;354:567-78.
25. Zebary A, Jangard M, Omholt K, Olding RB, Hansson J. KIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: a study of 56 cases. Br J Cancer. 2013;109:559-64.
26. Vandenhende C, Leroy X, Chevalier D, Mortuaille G. Sinonasal mucosal melanoma: retrospective survival study of 25 patients. J Laryngol Otol. 2012;126:147-51.
27. Koivunen P, Bäck L, Pukkilä M, Laranje J, Kinnunen I, Grénman R, et al. Accuracy of the current TNM classification in predicting survival in patients with sinonasal mucosal melanoma. Laryngoscope. 2012;122:1734-8.
28. Lin J, Li C, Wu G, Zeng Z. Analysis of prognostic factors of primary mucosal melanoma in nasal and oral cavity (article in Chinese). Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2012;26:49-32.
29. Thariat J, Poissonnet G, Marcé PY, Lattes L, Butori C, Guevara N, et al. Effect of surgical modality and hypofractionated split-course radiotherapy on local control and survival from sinonasal mucosal melanoma. Clin Oncol. 2011;23:579-86.
30. Borst A, Schwipper V. Primary mucosal malignant melanoma of the head and neck. Facial Plast Surg. 2011;27:237-42.

Cite this article as: Ojeda LP. Sinonasal mucosal melanomas in Quito, Ecuador. Int Surg J 2017;4:1009-13.